Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pacritinib + Talazoparib in MPNs Unresponsive to JAK2 Inhibition
NCT06218628Phase 1Recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Apr 2024
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of talazoparib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF) and 3 more (5 arms), sponsored by Fox Chase Cancer Center. Primary endpoint: Maximum Tolerated Dose at 6 years. Started Apr 2024; status: recruiting.
02
Drugs
talazoparib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)chronic myelomonocytic leukemia (CMML)polycythemia vera (PV)
Beyond the preview
Go deeper on NCT06218628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06218628.